Avencia Sánchez-Mejías is the co-founder and CEO of Integra Therapeutics. She has a solid scientific background in clinical genetics, molecular oncology and synthetic biology. She has spent her career at research institutes associated with university hospitals in several countries, including Spain, the United States and Singapore. In recent years, she has focused on transferring the knowledge generated at these institutions to society, through entrepreneurship.
José Ibeas is the Coordinator of the Clinical, Interventional, and Computational Nephrology Group at the Parc Taulí I3PT (CICN) He is co-director of the Master's in Artificial Intelligence in the Mixed Unit–Engineering School of the Autonomous University of Barcelona . He is the former president of VAS and the vice-president of GEMAV.
Antoni Matilla is the founder of the spinoff Biointaxis as well as Director of the Neurogenetics Research Unit at the Institute for Health Science Research Germans Trias i Pujol (IGTP). He is a researcher, doctor and entrepreneur with over thirty years of experience in research and business management in Catalonia, United States and United Kingdom. Since 1990, his research has focused on understanding and curing hereditary ataxias, a group of minority hereditary neurodegenerative diseases that have no cure so far.
Joan Bertran is a textile engineer, specializing in technical fabrics. In this field, he has worked in the aeronautics, automobile, renewable energy and, most recently, biomedical sectors. He has been director of operations and a member of the executive board at international textile companies. He has a master in Operations Management and an MBA. When a friend’s daughter died of cancer, he was inspired to become an entrepreneur in biotechnology.
Marta Guerrero is the cofounder of Retinset, a spinout of Medical Mix that focuses on developing retina treatments. She holds a PhD in pharmacy and has worked at multinational pharmaceutical companies, giving her a deep global vision of the various aspects to take into account when developing new drugs. She moved into entrepreneurship because that is how innovative scientific projects reach the market and can have an impact on society.
Pau Rodríguez is the CEO of Methinks AI, a startup founded in 2016 and based at Pier01. He is an industrial engineer and has an MBA from the SDA Bocconi School of Management. He is a member of the Spanish chapter of the Club of Rome, an organization working to find solutions to the challenges facing humanity. Pau has also been a professional rugby player: “In rugby everyone has a different profile, you work as a team and it’s important to trust your teammates...It’s similar to entrepreneurship.”